Of importance, the ATEMPT trial, which randomized patients with stage I HER2-positive breast cancer to T-DM1 versus paclitaxel/trastuzumab (TH), was designed to determine if treatment with T-DM1 was less toxic than TH. The gene discussed is ERBB2; the disease is breast carcinoma.